Insys Therapeutics Inc (NASDAQ:INSY), a pharmaceutical company, announced Q3 results that beat the Street view on both EPS and total revenues, fueled by an increase in sales for its Subsys fentanyl spray. The company reported Q3 adjusted EPS of $0.63, up from $0.39 in Q3 2013 and beating analyst estimates of $0.35. Total revenues of $58.3 million were up from $29.2 million in Q3 2013 and topped analyst projections of $57.0 million for the quarter. Revenues from Subsys fentanyl sublingual spray were $58.2 million, up 105% compared with Q3 2013 sales of $28.4 million.Insys Therapeutics Inc (NASDAQ:INSY) plans to advance four of its research and development programs into late-stage clinical trials in 2015 including Phase III clinical trials with three spray candidates: buprenorphine spray for acute pain, buprenorphine/ naloxone spray to treat opioid dependence, and ondansetron spray to treat nausea and vomiting. The company will also advance its pharmaceutical cannabidiol (CBD) candidate to treat Dravet Syndrome and Lennox-Gastaut Syndrome. Shares of INSY are trading within a 52-week range of $20.52 - $57.91.Click here for a free comprehensive Trend Analysis ReportNQ Mobile Inc (ADR) (NYSE:NQ) says subscribers of Russia's largest mobile operator Mobile Telesystems (MBT) will get access to its NQ Mobile Vault under a white label agreement. NQ is trading in the lower half of the 52-week range between $3.45 and $22.33. The mobile internet services provider said MTS will promote and distribute Mobile Vault, an on-device encryption of content and communication, through pre-load, SMS and social network campaigns, as well as direct at point-of-sale and app store availability. NQ Mobile Inc (ADR) (NYSE:NQ) closed in the lower half of the 52-week range between $12.65 and $22.40 on Monday.Click here for a free comprehensive Trend Analysis ReportMerck & Co., Inc. (NYSE:MRK) reported Tuesday promising results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir, a product to treat the chronic hepatitis C virus genotype 1 in treatment-naive and previously-treated patients. The results for HCV mono-infected treatment-naïve GT1 patients with cirrhosis and GT1 prior null-responders with or without cirrhosis treated with grazoprevir/elbasvir, with or without ribavirin, for 12 weeks showed rates of sustained viral response after the completion of therapy greater than, or equal to, 90% regardless of treatment duration or co-administration of RBV. The rate of virologic failure was 5% in treatment-naive cirrhotic patients and 3% in the null-responder population.Treatment-naive, non-cirrhotic mono-infected GT1 patients and non-cirrhotic HCV GT1 /HIV co-infected patients treated for 12 weeks with grazoprevir/elbasvir with or without RBV, demonstrated high rates of SVR12. The overall rate of virologic failure was 4%, including three breakthrough failures and four relapses, in both mono- and co-infected patients. In patients treated for eight weeks, the rate of virologic failure was 17%, with five relapses. The most common adverse events with or without RBV were fatigue (23%), headache (20%), nausea (15%) and diarrhea (10%). The final results were presented in oral sessions at the 65th American Association for the Study of Liver Diseases (AASLD) Annual Meeting (also known as The Liver Meeting) and published as separate papers online in The Lancet. Merck & Co., Inc. (NYSE:MRK)shares are up 1.25% at $59.54, with a 52-week range of $46.65 - $61.33.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
